INTRODUCTION
Lactoferrin (Lf), also called lactotransferrin [1, 2] , is an ironbinding glycoprotein present in most biological fluids of mammals [2, 3] and released from neutrophil granules during inflammatory responses [4] . Various biological functions of human Lf (hLf) and bovine Lf (bLf) have been demonstrated in host defence, especially in immunological response [5, 6] and antibacterial activity (for reviews see refs. [7, 8] ). In vitro studies on a wide range of Gram-negative micro-organisms suggested two reasons for the antimicrobial property of Lf: (i) the capacity of the protein to induce an iron-deficient environment [9] and (ii) its ability to interact with several components present at the surface of the bacterial membrane [10, 11] . With respect to the second reason, it has been shown that hLf can bind to lipopolysaccharide (LPS) [11] , a major component of the outer membrane of Gram-negative bacteria. In agreement with these findings, Appelmelk et al. [12] found high-affinity binding of hLf to the lipid A region of Escherichia coli LPS.
hLf-LPS interactions could also have relevance to the role of Lf in the inflammatory process. Indeed, hLf interacts with specific receptors present on mononuclear cells and regulates cytokine release [13] [14] [15] . This biological activity is inhibited in the presence of LPS suggesting that hLf loses the ability to bind to its receptor after hLf-LPS complex-formation [14] .
A knowledge of the hLf structure has enabled its binding sites for the lymphocytic receptor to be identified [16] [17] [18] [19] . Sequence analyses and crystallographic studies [20] [21] [22] have established that the hLf polypeptide chain is folded into two homologous inhibition of hLf-LPS interaction. Binding and competitive binding experiments performed with the N-tryptic fragment (residues 4-283), the C-tryptic fragment (residues 284-692) and the N2-glycopeptide (residues 91-255) isolated from hLf have demonstrated that the high-affinity binding site is located in the N-terminal domain I of hLf, and the low-affinity binding site is present in the C-terminal lobe. The inhibition of hLf-LPS interaction by a synthetic octadecapeptide corresponding to residues 20-37 of hLf and lactoferricin B (residues 17-41), a proteolytic fragment from bLf, revealed the importance of the 28-34 loop region of hLf and the homologous region of bLf for LPS binding. Direct evidence that this amino acid sequence is involved in the high-affinity binding to LPS was demonstrated by assays carried out with EGS-loop hLf, a recombinant hLf mutated at residues 28-34.
lobes, one N-terminal (residues 1-333), the other C-terminal (residues 345-692), each being organized into two domains NI, NII and CI, CII respectively. The primary structure of hLf shows about 70 % sequence identity with that of bLf and 59 % identity with that of human serum transferrin [23] . Three main regions located in the N-terminal domain I of hLf are involved in the hLf receptor-binding site: residues 4-6, 28-34 and 38-45 [19] . Comparison of the primary and tertiary structures of these regions with the homologous sequences of the C-terminal lobe of hLf and the N-and C-terminal lobes of serum transferrin revealed that residues 28-34 and residues 4-6 possess structural features specific to the N-terminal moiety ofhLf. The loop region (residues 28-34) is also present in lactoferricin H (residues 1-47) and lactoferricin B (residues 17-41), two peptides derived from partial proteolytic hydrolysis of hLf and bLf respectively [24, 25] . Both exhibit more potent antibacterial properties than the native proteins. It has been reported that the antibacterial sequences are precisely located in a loop region corresponding to residues 20-37 of hLf and 19-36 of bLf [24] .
Therefore the region containing amino acid residues 28-34 could play an important role not only in hLf binding to its specific receptor but also in its antimicrobial activity. As hLf binds to LPS, the interaction of amino acid sequence [28] [29] [30] [31] [32] [33] [34] of the protein with bacterial endotoxin could be suggested.
To check this hypothesis, we have studied the binding of hLf and bLf to E. coli 055B5 LPS. As human serum transferrin binds to LPS [26] , its ability to inhibit hLf-LPS interaction was also investigated. The domain of the hLf molecule implicated in the endotoxin recognition was specified by binding and competitive Abbreviations used: LPS, lipopolysaccharide; hLf, human lactoferrin; bLf, bovine lactoferrin; Lf, lactoferrin; rhLf, recombinant human lactoferrin. t To whom correspondence should be addressed.
binding assays performed with different hLf fragments: N-(residues 4-283) and C-(residues 284-692) fragments, N2-glycopeptide (residues 91-255) [27, 28] , a chemically synthesized octadecapeptide corresponding to residues 20-37 of hLf and lactoferricin B. Further, the hLf amino acid sequence responsible for LPS binding was more precisely defined by binding assays using EGS-loop recombinant hLf (EGS-loop rhLf), a mutated protein in which residues 28-34 of the N-terminal lobe were replaced by the homologous loop of the C-terminal lobe of hLf.
MATERIALS AND METHODS Materials
Lf was purified from pooled human lactoserum by ion-exchange chromatography as previously described [29] . bLf was kindly provided by Biopole (Brussels, Belgium). Homogeneity of the proteins was checked by SDS/PAGE [30] . Iron saturation of Lfs was carried out as described elsewhere [31] . Diferric hLf was submitted to mild tryptic hydrolysis to isolate the 30 kDa monoferric N-tryptic fragment (residues 4-283) and the 50 kDa monoferric C-tryptic fragment (residues 284-692) [27, 28] . The 20 kDa N2-glycopeptide (residues 91-255), which corresponds to the N-terminal domain II of hLf described by Anderson et al. [22] , was prepared from the tryptic hydrolysate of the N-tryptic fragment [28] . These fragments were further purified by gelfiltration chromatography on Bio-Gel P-60 for the N-and Ctryptic fragments and Bio-Gel P-30 for the N2-glycopeptide [27, 28] . An octadecapeptide corresponding to the amino acid sequence 20-37 of hLf was chemically synthesized by Dr. A. Tartar (Institut Pasteur, Lille, France). Lactoferricin B, a homologous peptide of hLf present in the N-terminal lobe of bLf (residues 17-41) was a gift from Morinaga Milk Industry Co. (Tokyo, Japan). Lf samples were passed through a Detoxi-Gel column (Pierce Chemicals Co., Rockford, IL, U.S.A.) before use. LPS contamination of Lfs, tryptic fragments and buffer solutions was less than 50 pg of endotoxin/mg of protein as estimated by Limulus amoebocyte lysate assays (QCL1000; BioWhittaker, Walkersville, MD, U.S.A.).
Dulbecco's PBS, pH 7.3, without Ca2+ and Mg2+, BSA recommended for ELISA experiments and E. coli 055B5 LPS were purchased from Sigma Chemicals (St. Louis, MO, U.S.A.). Ironfree human serum transferrin was from Behring (Marburg, Germany). PDI0 prepacked Sephadex G-25 M columns were from Pharmacia-LKB Biotechnology (Uppsala, Sweden). Pyrogen-free water was used to prepare all buffer solutions.
Expression and purificafton of recombinant hLf and EGS-loop hLf A full-length 2.3 kb cDNA coding for hLf was obtained from a human mammary-gland cDNA library (Clontech, Palo Alto, CA, U.S.A.) [32] . rhLf was expressed in BHK cells and purified as previously described [32] . The EGS-loop rhLf was obtained by site-directed mutagenesis of the cDNA coding sequence of Lf using the Sculptor in vitro mutagenesis system kit (Amersham International, Amersham, Bucks., U.K.). This mutated protein corresponds to hLf in which the sequence 28RKVRGPP34 was replaced by the sequence 365EGS3'7, located in the C-terminal lobe counterpart ( Figure 1) . A mutagenic oligonucleotide, 5'-TGG CAA AGG AAT ATG GAAGGT TCT GTC AGC TGC ATA AAG-3', was synthesized by Eurogentec (Seraing, Belgium) and used to replace nucleotides 433-451 (numbered as described by Rey et al. [21] ) by the sequence GAAGGTT. The template for the mutagenesis was the phage M13-mpll containing a 310 bp EcoRI-AccI fragment (nucleotides 295-606 of the coding sequence) obtained from the Lf cDNA cloned into pBluescript SK [32] . The presence of the mutated codons was confirmed by DNA sequence analysis [33] and the mutated EcoRI-AccI fragment was then ligated back into pBluescript with the 3' complementary part of the full-length cDNA of hLf. The resulting plasmid was then digested with XbaI and HindIII and the XbaI-HindIII fragment, made blunt-ended using the Klenow fragment of E. coli DNA polymerase I, was subcloned into the SmaI site of the expression vector pNUT, generously provided by Dr. R. Palmiter (University of Washington, Seattle, WA, U.S.A.) [34] . Transfection, expression in BHK cells and purification of the recombinant mutated protein were performed as previously described [32] . Both non-modified rhLf and EGSloop rhLf exhibited only one 80 kDa single protein band similar to that of human milk Lf, as checked by SDS/PAGE (results not shown).
Molecular modelling
The crystallographic data of diferric hLf and bLf were kindly provided by Professor E. N. Baker (Massey University, Palmerston North, New Zealand). Competitive binding assays Inhibition of 1251-hLf binding to LPS by unlabelled hLf, bLf and human serum transferrin was assessed in the presence of a 10-100-fold molar excess of each unlabelled protein. Radioimmunoassay tubes were coated with 5 ,ug/ml LPS and incubated overnight at 4 'C. The wells were blocked with PBS/0. 1 % BSA, washed and incubated with 2 jug/ml 1251-hLf overnight at 4 'C in the presence of increasing concentrations of unlabelled proteins. After three washes with PBS, the radioactivity was measured. A control of binding of radiolabelled protein to LPS-free tubes was carried out. Similar competitive experiments were performed between 2,tg/ml 125I-hLf and a 10-100-fold molar excess of unlabelled N-and C-tryptic fragments, N2-glycopeptide, synthetic octadecapeptide, lactoferricin B, rhLf and EGS-loop rhLf.
RESULTS

Interactions of hLf and bLf with LPS
Specific binding of hLf to immobilized E. coli 055B5 LPS was found to be concentration-dependent and saturable at about 450 nM (Figure 2 ). Scatchard-plot analysis revealed the presence of two binding sites: (i) a high-affinity binding site with a Kd of 3.6±1 nM; (ii) a low-affinity binding site with a Kd of 390 +20 nM ( Table 1) . As reported for hLf, bLf also exhibits concentration-dependent and saturable binding to LPS (Figure 2 ). According to Scatchard analysis, two binding sites were found for bLf: (i) a high-affinity binding site with a Kd of 4.5+ 2 nM, similar to the corresponding site of hLf; (ii) a low-affinity binding site with a lower Kd (576+30 nM) ( Table 1) .
The specificity of the 125I-hLf binding to LPS was checked in competitive studies with increasing concentrations of unlabelled hLf, bLf or human serum transferrin. As shown in Figure 3 , the interaction of hLf with LPS was 76+4 % inhibited by a 100-fold molar excess of unlabelled hLf, suggesting specific binding. At the same concentration, bLf inhibited the binding of 125I-hLf to LPS with an effectiveness similar to that of unlabelled human protein, 69 + 3 %. We have also investigated whether human serum transferrin, a protein closely related in structure to hLf, could inhibit these interactions. Our results revealed that human serum transferrin did not prevent LPS binding to hLf, no more than 12 + 3 % inhibition being detected (Figure 3) . These The results are typical of three separate experiments. To investigate whether the two types of LPS-binding sites present in the N-and C-tryptic fragments are similar to that found in the native protein, competitive binding assays between hLf and its proteolytic fragments were also performed ( Figure 5 ). Interaction of hLf with LPS was 75 + 3% inhibited by a 100-fold molar excess of N-tryptic fragment whereas inhibition by the C-tryptic fragment was only 50 + 3 %. No significant effect was observed with the N2-glycopeptide, no more than 20 + 3 % inhibition being measured. These results are in a good agreement with the experiments described above and prove the presence of the high-affinity LPS-binding LPS complex-formation. As illustrated in Figure 6 , 125I-hLf binding to LPS was 62+3% inhibited by the synthetic octadecapeptide corresponding to residues 20-37 of hLf and 82 + 3 % by lactoferricin B, a homologous peptide of hLf present in the Nterminal lobe of bLf. The binding assays of the two peptides to LPS were not performed because, in the absence of tyrosine residues, their radiolabelling involves the linkage of a chemical reagent to basic amino acids. We have previously reported that for hLf, this type of labelling could modify the capacity of the protein to interact with other molecules [18] .
Interaction of native and mutated rhLfs with LPS
To localize the amino acid sequence involved in the interaction with LPS, the 28RKVRGPP34 sequence present in the N-terminal lobe of hLf was replaced by the sequence 365EGS367 located in the C-terminal lobe of the protein. The (Figure 8 ). In contrast, native rhLf gave a similar inhibition curve to that of unlabelled hLf. These data confirm the results obtained in the binding experiments described above. 
Molecular modelling
We have compared the folding ofthe N-terminal peptide (residues 4-52) of hLf with the folding of the corresponding regions 'ound in the C-terminal lobe of hLf, N-terminal lobe of bLf and Nterminal lobe of rabbit serum transferrin. The N-terminal lobe of human serum transferrin possesses sequences homologous to that of rabbit protein [37] . However, crystallographic studies on human serum transferrin have not been reported.
As shown in Figure 9 , all four peptides have --c structures, which differ mainly in the loop equivalent to residues 28-34 of hLf. Very similar folding of this loop can be observed for hLf and bLf, whereas the corresponding loops of rabbit serum transferrin and the C-terminal part of hLf are longer or shorter respectively.
DISCUSSION
Antimicrobial properties of Lf [10, 38] and its role in immune defence during inflammation [5, 6] have been reported. Some of these activities are modulated, at least in part, by LPS-Lf complex-formation [14] . Recently, it has been demonstrated that inactivation of LPS by neutrophils is due to Lf secreted by neutrophil granules limiting inflammation and avoiding tissue damage by oxygen radicals [39] . However, up to now, no data on the region of Lf recognized by LPS are available. In the present study, two binding sites for E. coli 055B5 LPS have been found on hLf: a high-affinity (Kd 3.6±1 nM) site, and a low-affinity (Kd 390 + 20 nM) site which appears at high protein concentrations. The affinity constant corresponding to the high-affinity site is close to that obtained by Appelmelk et al. [12] for hLf binding to lipid A isolated from E. coli LPS (0.5 nM). These authors have not described a low-affinity site, probably because they worked only at very low hLf concentrations. A number of other proteins have also been reported to bind the lipid A region of LPS. These include bactericidal permeability-increasing protein, a cationic protein present in the granules of polymorphonuclear leucocytes [35] , and LPS-binding protein [40] , a serum protein. The binding of both proteins is specific and of high affinity with a Kd of 2-5 nM for the former [35] and 1 nM for the latter [40] . In our experiments, as well as in those reported by others [12, 35, 40] , the number ofbinding sites on different proteins per LPS molecule has not been determined. Indeed, it is well known that the molecular mass of LPS is heterogeneous since the endotoxin forms aggregates of different size. The capacity of 125I_ hLf to bind LPS was found to be specific, as 76 % inhibition of LPS-Lf interaction was obtained in the presence of a 100-fold molar excess of unlabelled protein.
We have located the hLf binding sites for LPS using different fragments obtained by partial proteolysis of hLf. The highaffinity site was found to be present in the N-terminal fragment (residues 4-283) of hLf (Kd 13 + 3 nM). It seems that the removal of the first three arginine residues from the N-tryptic fragment during tryptic hydrolysis of hLf [27] does not affect the binding of the fragment to LPS, since similar Kd values for whole native hLf and the N-tryptic fragment were obtained. The C-tryptic fragment possesses only low-affinity binding features and partially inhibits the hLf-LPS interaction. As no significant binding to endotoxin was measured with the N2-glycopeptide (91-255) which corresponds to N-terminal domain II of the protein, it can be assumed that the high-affinity recognition site is located in Nterminal domain I of hLf (residues 4-91 and 256-322). The glycan moiety of the protein is not involved in the binding of hLf to LPS, since domain I is not glycosylated. It has been shown that the lymphocyte-receptor-binding site of hLf is located in the N-terminal part of the molecule, corresponding to residues 4-52 [19] . As reported by Legrand et al. [19] , this domain contains three accessible areas, residues 4-6, 28-34 and 38-45, which are specific for the N-terminal moiety of hLf. The 28-34 amino acid sequence is present in the synthetic octadecapeptide, an antimicrobial cationic peptide corresponding to residues 20-37 of hLf which produced 62 % inhibition of hLf-LPS interaction. The loop region, which was found to be involved in the receptorbinding site, is somewhat different in the corresponding part of the C-terminal lobe [19] . This fact could explain why the Ctryptic fragment of hLf does not bind to LPS with high affinity.
Direct evidence that residues 28-34 are responsible for LPS binding was obtained by experiments performed with the EGSloop rhLf, a recombinant hLf in which residues 28-34 of the protein were replaced by the C-terminal loop counterpart. Our results revealed that this mutation on the whole protein leads to suppression of the high-affinity interactions between rhLf and LPS.
As for the C-terminal lobe of hLf, the homologous loop of the N-terminal lobe of serum transferrin exhibits specific structural features which could explain why serum transferrin, despite its ability to bind LPS, did not inhibit hLf-LPS interaction. Our results suggest the existence of different LPS-binding sites on transferrin and hLf, a hypothesis supported by the different biological activities reported for these two proteins [24] . Unlike hLf which possesses bactericidal activity, only a bacteriostatic effect of transferrin has been detected [24] . Nevertheless, the LPS-binding sites on serum transferrin have not been identified and further studies are necessary to elucidate the difference between Lf and serum transferrin in their molecular interactions with LPS.
Scatchard analysis also showed the presence of two LPSbinding sites on bLf, with similar Kd values to those obtained for hLf. Moreover, bLf inhibited hLf-LPS interaction. These results suggest that the same binding sites are present on bLf and hLf.
In fact, considering the high-affinity binding of Lfs to LPS, it can be observed that the loop regions originating from hLf (residues 28-34) and bLf exhibit similar structural features [41] . Lactoferricin B, a proteolytic peptide covering residues 17-41 of bLf, also decreased hLf binding to the endotoxin, but the inhibition was greater than that obtained with the octadecapeptide (82 % compared with 62%). This difference could be explained by a greater affinity of lactoferricin B for LPS, in agreement with its more potent activity against Gram-negative bacteria than the peptide derived from hLf [24] .
In conclusion, the loop region (28-34) of hLf is essential for the high-affinity binding of LPS. Considering the similar behaviour ofhLf and bLf towards LPS, it is reasonable to postulate that the above region is also important for bLf-LPS interaction. Moreover, as hLf has been reported to be a lipid A-binding protein [12] , it can be assumed that the loop sequences of hLf and bLf interact directly with the lipid A region of LPS.
Finally, the data on the hLf amino acid sequence involved in interaction with LPS could help to explain the modulation of some biological activities of this glycoprotein in the presence of endotoxin [13, 14] . In this context, our results are in agreement with the observation of Miyazawa et al. [14] that hLf loses the capacity to interact with its receptor present on differentiated HL60 cells after the formation of the hLf-LPS complex.
